COMBINATION CANCER THERAPIES

The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-rece...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ADAMS, Sharlene, LOUIS, Chrystal, U, CURLEY, Michael, LUGOVSKOY, Alexey, Alexandrovich, FINN, Gregory, J
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ADAMS, Sharlene
LOUIS, Chrystal, U
CURLEY, Michael
LUGOVSKOY, Alexey, Alexandrovich
FINN, Gregory, J
description The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3303398A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3303398A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3303398A13</originalsourceid><addsrcrecordid>eNrjZJBx9vd18vRzDPH091NwdvRzdg1SCPFwDXIM8HQN5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BxsYGxsaWFo6GxkQoAQAzJCBp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION CANCER THERAPIES</title><source>esp@cenet</source><creator>ADAMS, Sharlene ; LOUIS, Chrystal, U ; CURLEY, Michael ; LUGOVSKOY, Alexey, Alexandrovich ; FINN, Gregory, J</creator><creatorcontrib>ADAMS, Sharlene ; LOUIS, Chrystal, U ; CURLEY, Michael ; LUGOVSKOY, Alexey, Alexandrovich ; FINN, Gregory, J</creatorcontrib><description>The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20180411&amp;DB=EPODOC&amp;CC=EP&amp;NR=3303398A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20180411&amp;DB=EPODOC&amp;CC=EP&amp;NR=3303398A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ADAMS, Sharlene</creatorcontrib><creatorcontrib>LOUIS, Chrystal, U</creatorcontrib><creatorcontrib>CURLEY, Michael</creatorcontrib><creatorcontrib>LUGOVSKOY, Alexey, Alexandrovich</creatorcontrib><creatorcontrib>FINN, Gregory, J</creatorcontrib><title>COMBINATION CANCER THERAPIES</title><description>The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJBx9vd18vRzDPH091NwdvRzdg1SCPFwDXIM8HQN5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BxsYGxsaWFo6GxkQoAQAzJCBp</recordid><startdate>20180411</startdate><enddate>20180411</enddate><creator>ADAMS, Sharlene</creator><creator>LOUIS, Chrystal, U</creator><creator>CURLEY, Michael</creator><creator>LUGOVSKOY, Alexey, Alexandrovich</creator><creator>FINN, Gregory, J</creator><scope>EVB</scope></search><sort><creationdate>20180411</creationdate><title>COMBINATION CANCER THERAPIES</title><author>ADAMS, Sharlene ; LOUIS, Chrystal, U ; CURLEY, Michael ; LUGOVSKOY, Alexey, Alexandrovich ; FINN, Gregory, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3303398A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ADAMS, Sharlene</creatorcontrib><creatorcontrib>LOUIS, Chrystal, U</creatorcontrib><creatorcontrib>CURLEY, Michael</creatorcontrib><creatorcontrib>LUGOVSKOY, Alexey, Alexandrovich</creatorcontrib><creatorcontrib>FINN, Gregory, J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ADAMS, Sharlene</au><au>LOUIS, Chrystal, U</au><au>CURLEY, Michael</au><au>LUGOVSKOY, Alexey, Alexandrovich</au><au>FINN, Gregory, J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION CANCER THERAPIES</title><date>2018-04-11</date><risdate>2018</risdate><abstract>The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP3303398A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title COMBINATION CANCER THERAPIES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ADAMS,%20Sharlene&rft.date=2018-04-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3303398A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true